2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

Published

Journal Article

OBJECTIVE: To develop an evidence-based guideline on contraception, assisted reproductive technologies (ART), fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy assessment and management, and medication use in patients with rheumatic and musculoskeletal disease (RMD). METHODS: We conducted a systematic review of evidence relating to contraception, ART, fertility preservation, HRT, pregnancy and lactation, and medication use in RMD populations, using Grading of Recommendations Assessment, Development and Evaluation methodology to rate the quality of evidence and a group consensus process to determine final recommendations and grade their strength (conditional or strong). Good practice statements were agreed upon when indirect evidence was sufficiently compelling that a formal vote was unnecessary. RESULTS: This American College of Rheumatology guideline provides 12 ungraded good practice statements and 131 graded recommendations for reproductive health care in RMD patients. These recommendations are intended to guide care for all patients with RMD, except where indicated as being specific for patients with systemic lupus erythematosus, those positive for antiphospholipid antibody, and/or those positive for anti-Ro/SSA and/or anti-La/SSB antibodies. Recommendations and good practice statements support several guiding principles: use of safe and effective contraception to prevent unplanned pregnancy, pre-pregnancy counseling to encourage conception during periods of disease quiescence and while receiving pregnancy-compatible medications, and ongoing physician-patient discussion with obstetrics/gynecology collaboration for all reproductive health issues, given the overall low level of available evidence that relates specifically to RMD. CONCLUSION: This guideline provides evidence-based recommendations developed and reviewed by panels of experts and RMD patients. Many recommendations are conditional, reflecting a lack of data or low-level data. We intend that this guideline be used to inform a shared decision-making process between patients and their physicians on issues related to reproductive health that incorporates patients' values, preferences, and comorbidities.

Full Text

Duke Authors

Cited Authors

  • Sammaritano, LR; Bermas, BL; Chakravarty, EE; Chambers, C; Clowse, MEB; Lockshin, MD; Marder, W; Guyatt, G; Branch, DW; Buyon, J; Christopher-Stine, L; Crow-Hercher, R; Cush, J; Druzin, M; Kavanaugh, A; Laskin, CA; Plante, L; Salmon, J; Simard, J; Somers, EC; Steen, V; Tedeschi, SK; Vinet, E; White, CW; Yazdany, J; Barbhaiya, M; Bettendorf, B; Eudy, A; Jayatilleke, A; Shah, AA; Sullivan, N; Tarter, LL; Birru Talabi, M; Turgunbaev, M; Turner, A; D'Anci, KE

Published Date

  • April 2020

Published In

Volume / Issue

  • 72 / 4

Start / End Page

  • 529 - 556

PubMed ID

  • 32090480

Pubmed Central ID

  • 32090480

Electronic International Standard Serial Number (EISSN)

  • 2326-5205

Digital Object Identifier (DOI)

  • 10.1002/art.41191

Language

  • eng

Conference Location

  • United States